Elucidating the immune mechanism of CD8+ TILs/PD‐L1 TC and CD8+ TILs/CD4+CD25+FOXP3+ Treg ratios may provide strategies for developing immunotherapy for ESCC. Here, CD4 is linked to esophageal squamous cell carcinoma.